Preview

Злокачественные опухоли

Расширенный поиск

РАННИЙ РАК МОЛОЧНОЙ ЖЕЛЕЗЫ. РАЗЛИЧНЫЕ АСПЕКТЫ КОМБИНИРОВАННОГО ЛЕЧЕНИЯ. НОВЫЕ ПОДХОДЫ К НЕОАДЪЮВАНТНОЙ ТЕРАПИИ РАННЕГО HER2 ПОЗИТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ

https://doi.org/10.18027/2224-5057-2013-1-35-40

Полный текст:

Аннотация

Опыт применения препаратов, блокирующих HER2-рецепторы, в клинической практике насчитывает около 15 лет. За это время произошла серьезная эволюция наших представлений о месте и показаниях к назначению этих препаратов при HER2-позитивном раке молочной железы. Доказано, что неоадъювантная таргетная терапия раннего HER2-позитивного рака молочной железы уменьшает риск рецидивирования и метастазирования. Тем не менее, блокирование HER2-рецепторов при раннем раке молочной железы оставляет множество открытых вопросов. Применение таргетных препаратов в неоадъювантном режиме является перспективным и требует продолжения исследований.

Об авторе

Д. Д. Сакаева
ГБУЗ Республиканский клинический онкологический диспансер МЗ РБ
Россия


Список литературы

1. Bear H. D. Indications for neoadjuvant chemotherapy for breast cancer. Semin. Oncol. — 1998; 25: 3.

2. Hortobagyi G. N., Blumenschein G. R., Spanos W. et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer. — 1983; 51: 763.

3. Hortobagyi G. N., Ames F. C., Buzdar A. U. et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. — 1988; 62: 2507.

4. Hortobagyi G. N. Comprehensive management of locally advanced breast cancer.Cancer. — 1990; 66: 1387.

5. Fisher B., Bryant J., Wolmark N. et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. — 1998; 16: 2672.

6. Wolmark N., Wang J., Mamounas E. et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. — 2001; 30: 96-102.

7. Bear H. D., Anderson S., Brown A. et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. — 2003; 21: 4165-4174.

8. Van der Hage J. A., van de Velde C. J. H, Julien J-P et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. — 2001; 19:4224-4237.

9. Mieog S., van der Hage J., van de Velde C. J. H. Preoperative Chemotherapy for Women with Operable Breast Cancer (Review) 1. John Wiley & Sons, Ltd. January 24 [epub ahead of print],

10. DOI: 10.1002 / 14651858. CD005002.

11. Kuerer H. M., Newman L. A., Smith T. M. et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. — 1999;17: 460-469.

12. Guarneri V., Broglio K., Kau S-W et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. — 2006; 24: 1037-1044.

13. von Minckwitz G., Kaufmann M., K mmel S. et al. Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline- taxane + / – trastuzumab containing chemotherapy. Cancer Res. — 2009; 69 (suppl.): 79.

14. Ring A. E., Smith I. E., Ashley S. et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer. — 2004; 91: 2012-2017.

15. Colleoni M. Preoperative systemic treatment: Prediction of responsiveness. Breast 2003; 12 (suppl 1, abstr S35): S13.

16. Esserman L. J., Perou C., Cheang M. et al. Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007 / 150012, ACRIN 6657). ASCO Meeting Abstracts, 2009 (LBA515).

17. Slamon D. J., Leyland-Jones B., Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. — 2001; 344: 783.

18. Pritchard K. I., Messersmith H., Elavathil L. et al. HER2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol. — 2008; 26: 736-744.

19. Di Leo A., Desmedt C., Bartlett J. M. S. et al. HER2 and TOP2A as predictive markers for anthracycline containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol. — 2011;12: 1134-1142.

20. Hayes D. F., Thor A. D., Dressler L. G. HER2 and response to paclitaxel in node- positive breast cancer. N Engl J Med. — 2007; 357: 1496-1506.

21. Kaufmann M., von Minckwitz G., Bear H. D. et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. — 2007; 18:1927-1934.

22. Buzdar A. U., Ibrahim N. K., Francis D. et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermalgrowth factor receptor 2-positive operable breast cancer. J Clin Oncol. — 2005; 23:3676-3685.

23. Buzdar A. U., Valero V., Ibrahim N. K. et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor-2 positive operable breast cancer: an update

24. of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. — 2007;13: 228-233.

25. Gianni L., Eiermann W., Semiglazov V. et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. — 2010; 375: 377-384.

26. Untch M., Rezai M., Loibl S. et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. — 2010;

27. : 2024-2031.

28. von Minckwitz G., Rezai M., Loibl S. et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncolм 2010; 28:2015-2023.

29. Семенова А. И. Основные принципы системной терапии позитивного рака молочной железы. Практическая онкология. – Т.11. – № 4. – 2010. – с. 239-246.

30. Jobnston S., Trudeau M., Kaufman B. еt al Phase II study of predictive biomarker profails for response targeting human epidermal growth factor receptor 2 (HER2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol. — 2008; 26: 1066-1072.

31. Baselga J., Bradbury I., Eidtmann H. et al. Lapatinib with trastuzumab for HER2- positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. — 2012; 379: 633-640.

32. Untch M., Loibl S., Bischoff J. et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG44): a randomised phase 3 trial. Lancet Oncol. — 2012; 13: 135-144.

33. Guarneri V., Frassoldati A., Bottini A. et al. Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol. — 2012; 30: 1989-1995.

34. Gianni L., Pienkowski T., Im Y-H et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (‘NeoSphere’). Cancer Res. — 2010; 70 (24 Suppl.): Abstr S3–2.

35. Baselga J., Cort s J., Kim S-B et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. — 2012; 366: 2.

36. Blackwell K. L., Burstein H. J., Storniolo A. M. et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. — 2010; 28:

37. Sousa B., Cardoso F. Neoadjuvant treatment for HER2-positiv and tripl-negativ breast cancer. Ann Oncol. — 2012; 23: 237-242.


Для цитирования:


Сакаева Д.Д. РАННИЙ РАК МОЛОЧНОЙ ЖЕЛЕЗЫ. РАЗЛИЧНЫЕ АСПЕКТЫ КОМБИНИРОВАННОГО ЛЕЧЕНИЯ. НОВЫЕ ПОДХОДЫ К НЕОАДЪЮВАНТНОЙ ТЕРАПИИ РАННЕГО HER2 ПОЗИТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ. Злокачественные опухоли. 2013;(1):35-40. https://doi.org/10.18027/2224-5057-2013-1-35-40

For citation:


Sakaeva V.V. Early breast cancer. Different aspects of combined treatment. New approaches in neoadjuvant treatment of early HER2-positive breast cancer.. Malignant tumours. 2013;(1):35-40. (In Russ.) https://doi.org/10.18027/2224-5057-2013-1-35-40

Просмотров: 286


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2224-5057 (Print)
ISSN 2587-6813 (Online)